Privacy, Disclaimer & General Conditions

News Octimet Oncology, advised by Argo, secures a license from Janssen Pharmaceutica and a 11.3 million capital increase
23 January 2017

Argo advised the founders and management of the Belgian biotech start-up Octimet Oncology NV on securing a license from Janssen Pharmaceutica in relation to the development of a clinically de-risked MET kinase inhibitor for the treatment of solid cancers and on completing a capital increase of 11.3 million EUR, funded by amongst others V-Bio Ventures, Fund+ and DROIA Oncology Ventures.

Back to news
Stay in the loop.